N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
University of California, San Francisco
University of California, San Francisco
Mayo Clinic
Jonsson Comprehensive Cancer Center
Thomas Jefferson University
Jonsson Comprehensive Cancer Center
University of Southern California
Northwestern University
Memorial Sloan Kettering Cancer Center